Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2/3 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 242Carboplatin 137Nivolumab 132Gemcitabine 127Paclitaxel 116Cisplatin 105Cyclophosphamide 97Bevacizumab 93Dexamethasone 78Injections 75Pemetrexed 71Docetaxel 71Fluorouracil 68Capecitabine 65Rituximab 61Cetuximab 61atezolizumab 59130-nm albumin-bound paclitaxel 59Oxaliplatin 58Leucovorin 57Ipilimumab 54fludarabine 50Lenalidomide 47Azacitidine 40Irinotecan 39venetoclax 38Fulvestrant 38Albumin-Bound Paclitaxel 36Prednisone 35Trastuzumab 34

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × INDUSTRY × cedazuridine × Clear all
NCT04657081 2025-12-08

Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)

Taiho Oncology, Inc.

Phase 1/2 Active not recruiting
101 enrolled 1 FDA
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02103478 2024-08-27

Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)

Astex Pharmaceuticals, Inc.

Phase 1/2 Completed
130 enrolled 34 charts 1 FDA
Myeloid

Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡